INDIVIDUAL PROGNOSTICATION OF GASTROINTESTINAL STROMAL TUMORS BASED ON CLINICAL-MORPHOLOGICAL AND MOLECULAR-GENETIC MARKERS

Authors

  • Xoldarova Erkinoy Andijan State Medical Institute Department of Histology and Cytology Author
  • Xoldarova Erkinoy Andijan State Medical Institute Department of Histology and Cytology Author

Keywords:

Keywords: gastrointestinal stromal tumor; GIST; prognosis; KIT; PDGFRA; DOG1; mitotic index; molecular markers; personalized medicine.

Abstract

 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract and are characterized by marked biological heterogeneity. Accurate prognosis cannot be based on tumor size alone because anatomic site, mitotic activity, tumor rupture, histological phenotype, immunohistochemical profile, and driver genotype materially modify recurrence risk and treatment sensitivity. The purpose of this review was to systematize clinically relevant prognostic markers and to formulate an integrated approach to individualized risk assessment. A structured narrative review of contemporary international guidelines, peer-reviewed studies, and Uzbekistan-based publications and clinical protocols was performed, with emphasis on evidence concerning KIT, PDGFRA, SDH-complex abnormalities, BRAF/NF1 alterations, DOG1/CD117 expression, mitotic index, tumor location, size, and rupture. The synthesis demonstrates that classical morphology remains the foundation of risk stratification, while molecular-genetic characterization refines both prognosis and therapeutic prediction. KIT exon 11 deletions involving codons 557/558, KIT exon 9 alterations, SDH-deficient status, and selected wild-type molecular subgroups may be associated with distinct clinical behavior; in contrast, PDGFRA-mutant gastric GISTs, particularly non-D842V variants, often show a more indolent phenotype, although genotype must always be interpreted together with morphology and stage. A practical individual prognostic model should therefore combine clinical stage, anatomic site, tumor size, mitotic count per 5 mm², rupture status, resection margin, immunophenotype, and mutational profile. Such integration provides a stronger basis for recurrence-risk estimation, selection of adjuvant tyrosine kinase inhibitor therapy, and personalized surveillance than any single marker used in isolation.

References

1.Casali, P. G., Blay, J. Y., Abecassis, N., et al. (2022). Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 33(1), 20-33. https://doi.org/10.1016/j.annonc.2021.09.005

2.WHO Classification of Tumours Editorial Board. (2020). Soft Tissue and Bone Tumours. WHO Classification of Tumours, 5th ed., Vol. 3. Lyon: International Agency for Research on Cancer.

3.Hirano, H., Naito, Y., Takahashi, T., et al. (2026). Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025). Gastric Cancer. https://doi.org/10.1007/s10120-026-01773-4

4.von Mehren, M., Kane, J. M., Bui, M. M., et al. (2022). Gastrointestinal Stromal Tumors, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20(11), 1204-1230.

5.Serrano, C., George, S., & Heinrich, M. C. (2024). Genomic profiling in GIST: Implications in clinical outcome and future challenges. Neoplasia, 48, 100959. https://doi.org/10.1016/j.neo.2023.100959

6.Joensuu, H., Vehtari, A., Riihimäki, J., et al. (2012). Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. The Lancet Oncology, 13(3), 265-274.

7.Heinrich, M. C., Owzar, K., Corless, C. L., et al. (2008). Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumors. Journal of Clinical Oncology, 26(33), 5360-5367.

8.Yakubov, Y. K., Khudayberdieva, M. Sh., & Khudoyorov, S. S. (2021). Gastrointestinal stromal tumors (GIST): Clinical cases. Norwegian Journal of Development of the International Science, 69(1), 25-34. https://doi.org/10.24412/3453-9875-2021-69-1-25-34

9.Semash, K., & Dzhanbekov, T. (2025). Redefining the treatment paradigm for esophageal gastrointestinal stromal tumors: The emerging role of endoscopic resection. World Journal of Gastroenterology, 31(24), 106440. https://doi.org/10.3748/wjg.v31.i24.106440

10.Ministry of Health of the Republic of Uzbekistan. (2025). National clinical protocol: Extra-organ retroperitoneal tumors; practical recommendations for drug treatment of gastrointestinal stromal tumors (GIST). Appendix to Order No. 180 of 23 June 2025. Tashkent: Ministry of Health of the Republic of Uzbekistan.

Downloads

Published

2026-10-27